Seeking Alpha

The FDA has approved Novartis' (NVS) Signifor drug to treat sufferers of Cushing's disease who...

The FDA has approved Novartis' (NVS) Signifor drug to treat sufferers of Cushing's disease who aren't eligible for surgery. Cushing's disease is a rare hormone condition that can cause obesity, skin that bruises easily and excess hair growth. Novartis will have to carry three more analyses of Signifor for high sugar levels in patients' blood, the risks stemming from such levels, and for monitoring the long-term use of the treatment.
Comments (1)
  • Reveszla
    , contributor
    Comment (1) | Send Message
     
    Signifor is a novel cyclohexapeptidic analogue of Somatostatin and binds with high affinity to the sst5 receptor, resulting in the inhibition ACTH-release (ACTH=adrenocorticotro... hormone). Since Cushing's disease is due to overproduction of ACTH, Signifor is the drug of choice for its treatment. First generation Somatostatin analogues like Octreotide and Lanreotide had a 40-500 fold lower affinity to the sst5 receptor and hence are less effective.
    17 Dec 2012, 05:43 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector